Table 4.

Updated treatment hazard ratios (HRs) for progression-free and overall survival (ratio of experimental to control) for the first stage analysis of GOG-182/ICON5 presented at the American Society of Clinical Oncology in June 2006^*

	Progression-free survival	Overall survival
Experimental regimen	Crude HR (95% CI)	Crude HR (95% CI)
Gemcitabine triplet	0.99 (0.88 to 1.11)	0.98 (0.84 to 1.14)
Doxil triplet	1.00 (0.89 to 1.12)	0.97 (0.83 to 1.14)
Topotecan doublet	1.09 (0.98 to 1.22)	0.07 (0.92 to 1.24)
Gemcitabine doublet	1.05 (0.94 to 1.18)	1.04 (0.88 to 1.21)

^*CI = confidence interval; GOG = Gynecologic Oncology Group; ICON = International Collaborative Ovarian Neoplasm Studies.